STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

News

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Rhea-AI Summary
Tonix Pharmaceuticals announces enrollment in a Phase 1 clinical trial for TNX-1500 to prevent kidney allograft rejection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
News

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. to present at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. to present at World Vaccine Congress Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
News

Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference

Rhea-AI Summary
Tonix Pharmaceuticals presents TNX-2900 program for Prader-Willi syndrome at FPWR conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
News

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has been granted a European patent for its magnesium-containing oxytocin formulations for treating pain, including migraine headaches. The patent is expected to provide market exclusivity in Europe until 2036. The company also holds U.S. patents that provide market exclusivity in the U.S. until 2036. Tonix completed enrollment in its Phase 2 study for the prevention of migraine headache and expects topline results in December 2023. The company believes that its strong patent position and unique approach have the potential to help chronic migraine sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
News

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces public offering of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
offering
News

Tonix Pharmaceuticals Announces Proposed Public Offering

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock and warrants in a public offering, with the proceeds going towards working capital, facilities, and product acquisition or licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.43%
Tags
offering
-
News

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has announced that the University of North Carolina Institute for Trauma Recovery has received a $3 million grant from the Department of Defense to investigate the potential of TNX-102 SL to reduce the frequency and severity of adverse effects of acute trauma. The proposed trial will examine the safety and efficacy of TNX-102 SL in reducing posttraumatic neuropsychiatric sequelae among trauma survivors. The trial will enroll approximately 180 participants and is anticipated to begin in early 2024. This funding and trial could lead to the development of a new treatment option for trauma and traumatic stress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
none
-
News

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023

Rhea-AI Summary
Tonix Pharmaceuticals presents positive data on mTNX-1700 in treating colorectal cancer at CICON23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
clinical trial
News

Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress

Rhea-AI Summary
Tonix Pharmaceuticals presents data on the proposed mechanism of TNX-1900 in treating chronic migraine at the 2023 International Headache Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
clinical trial

FAQ

What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?

The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.19 as of November 22, 2024.

What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?

The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 38.2M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.

Stock TNXP logo
Tonix Pharmaceuticals Holding Corp.

Nasdaq:TNXP

TNXP Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends

TNXP Stock Data

38.16M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHATHAM